Depression Biomarkers
Depression
DiscoveryActive
Key Facts
About Paradise Genomics
Paradise Genomics is a private, pre-revenue diagnostics company leveraging over 30 years of collective founder experience in genomics to discover novel biomarker signatures. The company emerged from GenUs BioSystems, a contract lab with a strong track record, and now aims to validate and commercialize its discoveries through partnerships with diagnostic and pharmaceutical companies. Its core value proposition is a proprietary bioinformatics process that claims unmatched sensitivity and precision in unlocking a unique region of the transcriptome for actionable genomic data.
View full company profileTherapeutic Areas
Other Depression Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| Depression Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| Depression Study | Sun Valley Research Center | Not Disclosed |
| eTNS Platform | NeuroSigma | Unknown |
| ALM003 | Almatica Pharma | Phase 3 |
| ALM014 | Almatica Pharma | Pivotal BA/BE |
| NRCT-101SR | Neurocentria | Phase 2b/3 |
| Starstim for Depression | Neuroelectrics | Phase 1/2 |
| Home-tDCS Depression Trial | Soterix Medical | N/A (Device-enabled trial) |
| BPL-003 | AtaiBeckley | Phase 2 |
| VLS-01 | AtaiBeckley | Phase 2 |
| NC-2800 | Nippon Chemiphar | Phase 2a |